Pathological complete response following neoadjuvant chemoimmunotherapy in cancer of unknown primary: a case report
Neoadjuvant chemoimmunotherapy may provide clinical benefit in CUP with intrathoracic nodal metastasis, even without a confirmed primary tumor. Integration of MDT decision-making and MRD monitoring may provide valuable information to inform perioperative strategies and optimize patient prognosis.
Authors
- Y-L. Peng
- Hong-Yi Zhu
- Hui-Bing Gao
Institutions
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.21037/tlcr-2025-1-1387
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00